Pyxis Oncology, Inc. Share Price
PYXSPyxis Oncology, Inc. Stock Performance
Open $2.34 | Prev. Close $2.37 | Circuit Range N/A |
Day Range $2.23 - $2.40 | Year Range $0.97 - $5.55 | Volume 16,499 |
Average Traded $2.31 |
Pyxis Oncology, Inc. Share Price Chart
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Pyxis Oncology, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jul-26 | $2.34 | $2.24 | +0.00% |
20-Jul-26 | $2.34 | $2.24 | -5.49% |
17-Jul-26 | $2.25 | $2.37 | +6.28% |
16-Jul-26 | $2.31 | $2.23 | -8.23% |
15-Jul-26 | $2.30 | $2.43 | +6.11% |
14-Jul-26 | $2.37 | $2.29 | -5.76% |
13-Jul-26 | $2.52 | $2.43 | -9.33% |